A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Fiche publication
Date publication
mai 2023
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LANG Hervé, Dr LINDNER Véronique, Dr MASSFELDER Thierry
Tous les auteurs :
Béraud C, Bidan N, Lassalle M, Lang H, Lindner V, Krucker C, Masliah-Planchon J, Potiron E, Lluel P, Massfelder T, Allory Y, Misseri Y
Lien Pubmed
Résumé
Despite the significant advances in the management of advanced prostate cancer (PCa), metastatic PCa is currently considered incurable. For further investigations in precision treatment, the development of preclinical models representing the complex prostate tumor heterogeneity are mandatory. Accordingly, we aimed to establish a resource of patient-derived xenograft (PDX) models that exemplify each phase of this multistage disease for accurate and rapid evaluation of candidate therapies.
Mots clés
PARP inhibitor, PDX, castrate-resistant prostate cancer (CRPC), genomic characteristics, metabolism, neuroendocine tumors, prostate cancer, tumor heterogeneity
Référence
Front Oncol. 2023 05 26;13:1130048